GSK decides against selling established portfolio brands; More solid data for Pfizer's Xalkori;

@FiercePharma: Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. FierceVaccines article | Follow @FiercePharma

@EricPFierce: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. News | Follow @EricPFierce

@CarlyHFierce: Universal flu vaccine developer BiondVax mulling IPO. Globes | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) today said it had decided against selling off its portfolio of older drugs. Release

> An estimated 58,000 newborns in India died last year from antibiotic resistant infections, a number being described as an epidemic. Story

> Pfizer ($PFE) says data from a Phase III study shows that its targeted cancer drug Xalkori (crizotinib) significantly extended progression-free survival in previously-untreated patients with a particular form of non-small cell lung cancer. Story

> Pfizer will share information on drugs with the World Anti-Doping Agency (WADA) to allow it to test for performance-enhancing substances in athletes. Story

> The FDA approved Amgen's ($AMGN) Blincyto (blinatumomab), the first of a new class of immunotherapies that promise to change the standard of care in blood cancer. Story

> The FDA has established new standards for using prescription drugs by women who are breastfeeding children. Release

Medical Device News

@FierceMedDev: ICYMI: Illumina and Sequenom lay ongoing prenatal diagnostic patent feud to rest. Article | Follow @FierceMedDev

@EmilyWFierce: Britain's BTG scoops up pulmonology outfit PneumRx for up to $475M. Story | Follow @EmilyWFierce

> Zimmer makes a divestiture proposal to appease EU regulators in Biomet acquisition. Item

> Hospital requires use of wireless, wearable sensors to prevent bedsores. News

> HeartFlow's noninvasive test for coronary artery disease cleared by FDA. More

Biotech News

@FierceBiotech: Party time at Array as Novartis bows out of PhIII binimetinib cancer program. Report | Follow @FierceBiotech

@JohnCFierce: College students with big ideas can shoot for some seed money from Xfund. Harvard-based--$100M. More from the WSJ | Follow @JohnCFierce

@DamianFierce: Blincyto, which sounds like it's related to the cells of blintzes, is the name of Amgen's new cancer drug. More | Follow @DamianFierce

> Scientists herald a breakthrough in reversing spinal damage. More

> J&J launches PhII lymphoma study for daratumumab. Item

> Biotech partners at Allena fund a march toward PhIII with $25M venture round. Report

Vaccines News

> Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. Article

> Universal flu vax developer BiondVax mulling IPO: Globes. Item

> GSK, NIH gear up for Ebola vaccine trial expansion after success in PhI. Report

> Merck, NewLink Ebola vaccine trial shows no serious side effects so far. Story

> Novartis' Fluad off the hook in Italy following 19 deaths. Article

Pharma Manufacturing News

> EMA clears Novartis Fluad in deaths in Italy. Item

> Johnson Matthey buys former Glaxo facility in Scotland. More

> Strides Arcolab begins construction of $60M Malaysia facility. Report

> Some Indian drugmakers routinely toss out bad test results: Bloomberg. Story

> Germany, EU, join U.S. in banning India-made Ranbaxy products. Article

And finally... Healthcare spending was up 3.6% in the U.S. last year, the smallest rise in more than half a century. Story

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.